# XFOR earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/XFOR) · [Earnings tab](https://www.lopjlb.com/stock/XFOR?tab=earnings)

Updated: 2026-08-06T07:35:02

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of earnings CallCards, X4 Pharmaceuticals moved from early-stage cash constraints and tentative development timelines to a clearer commercial and regulatory outlook. In early 2023 the company highlighted a modest cash runway into early 2024 while preparing Phase 3 data for its WHIM‑syndrome candidate, Mavorixafor, and planning an NDA filing. By mid‑2023, positive Phase 3 results and a sizable debt facility expanded cash to roughly $140 million, extending runway into 2025 and enabling a Phase 2 chronic neutropenia read‑out that suggested G‑CSF reduction. The third quarter confirmed NDA acceptance for Priority Review with a PDUFA deadline in April 2024 and solidified the chronic neutropenia Phase 3 trial design. After a quiet period in late‑2023 and early‑2024, the firm launched XOLREMDI for WHIM in mid‑2024, generating $2.5 million in sales within 7½ months and later reporting $3.5 million cumulative revenue. Simultaneously, the 4WARD Phase III trial in chronic neutropenia progressed toward enrollment completion in late 2025, with management confidence reinforced in early 2025. A restructuring announced in early 2025 aims to cut $30‑35 million annually, further stabilizing the balance sheet and extending cash runway into H1 2026.

## Latest CallCard · Q1

X4 Pharma advances 4WARD Phase III in chronic neutropenia with enrollment on track for H2 2025, WHIM sales $3.5M cumulative, cash runway into H1 2026, restructuring to cut $30-35M annually.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management expressed confidence in 4WARD trial design, enrollment pr

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2025 Q1:** X4 Pharma advances 4WARD Phase III in chronic neutropenia with enrollment on track for H2 2025, WHIM sales $3.5M cumulative, cash runway into H1 2026, restructuring to cut $30-35M annually.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management expressed confidence in 4WARD trial design, enrollment pr
- **2024 Q4:** X4 Pharmaceuticals launched XOLREMDI for WHIM syndrome in mid-2024, generating $2.5M in 7.5 months; advancing Phase 3 4WARD trial in chronic neutropenia with protocol refinements, targeting enrollment completion Q3/Q4 2025 and data H2 2026; restructuring to cut $30-35M annually; cash runway into H1 
- **2024 Q3:** —
- **2024 Q1:** —
- **2023 Q4:** —
- **2023 Q3:** X4 Pharma's NDA for mavorixafor in WHIM syndrome accepted for FDA Priority Review with PDUFA April 30, 2024; Phase 3 CN trial design finalized, initiation H1 2024; cash ~$140M funds ops into 2025.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlighted NDA acceptance with Priority Review, P
- **2023 Q2:** X4 Pharma reports positive WHIM Phase 3 data, plans imminent NDA submission, $142M cash + $115M debt facility extends runway to 2025; CN Phase 2 shows robust ANC increases enabling G-CSF reduction; Phase 3 CN trial to start H1 2024 targeting ~15k US patients.','tone': {'mgmt': 0.8, 'mgmt_rationale':
- **2023 Q1:** X4 Pharmaceuticals reports Q1 2023 financials with $94.4M cash runway into Q2 2024; advancing Mavorixafor for WHIM syndrome with Phase 3 data presentations in May, NDA filing H2 2023, potential US launch H1 2024; Phase 2 chronic neutropenia data expected Q2/Q3.','tone': {'mgmt': 0.7, 'mgmt_rationale

## Theme arcs

- **Cash runway and capital position** (improving): Cash grew from $94.4M (Q1 2023) to $140M+ with a $115M debt facility, extending runway to 2025 and later into H1 2026 after restructuring.
- **Regulatory progress for WHIM therapy** (improving): Moved from planned NDA filing (H2 2023) to FDA Priority Review acceptance (Q3 2023) and product launch (mid‑2024).
- **Clinical development for chronic neutropenia (4WARD)** (improving): Phase 2 data reported (Q2 2023), Phase 3 design finalized (Q3 2023), enrollment on track for H2 2025, data expected H2 2026.
- **Commercial launch and sales** (new): XOLREMDI launched mid‑2024, generating $2.5M in 7.5 months and $3.5M cumulative by Q1 2025.
- **Cost restructuring** (new): Announced restructuring to cut $30‑35M annually (Q4 2024) and ongoing in 2025.

## Guidance path

2023 Q1:vague → 2023 Q2:vague → 2023 Q3:vague → 2023 Q4:vague → 2024 Q1:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/XFOR`